Orenitram ER (Treprostinil Diolamine) Patent Expiration, LOE Window & CMS Spending

Orenitram ER (Treprostinil Diolamine) by United Therapeutics: FDA Orange Book core substance LOE 2028-12-15 (last listed 2031-08-11), 0 AB generics, $305.8M 2024 CMS Part D & Medicaid spend, and 25 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUnited Therapeutics
FDA Application & PathwayN203496 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2028-12-15
Last Listed Patent or Exclusivity Date2031-08-11
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$305.8M
2024 Medicare Part D Spend$230.4M
2024 Medicaid Spend$75.4M
Reported Wholesale Price Change (CA SB 17)25 WAC filings (max 19.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for United Therapeutics across sibling Meru public-data platforms.